FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS
June 19th 2018The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.
It's Not Quite Prime Time for Up-Front Genomic Sequencing in Early-Stage CRC
June 11th 2018Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.